Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p322 | Osteoporosis: evaluation and imaging | ECTS2016

The essential role of bone biochemistry in the treatment of osteoporosis with rPTH therapy: a large study of over 450 patients

Casey Miriam , Healy Martin , McCarroll Kevin , Sidique Najia , Mahon James , Fallon Nessa , Walsh Bernard , Lannon Rosaleen

The effect of recombinant parathyroid hormone therapy as an anabolic agent has delivered great success in the treatment of osteoporosis. Although a treatment response is still defined in DXA terms, initial scans can fail to detect an increase in BMD since the collagen deposited in bone may not yet have mineralized. It is key therefore that an early response is detected biochemically and the physician can be reassured that the bone is not adynamic, the patient is compliant and ...

ba0005p406 | Osteoporosis: treatment | ECTS2016

Adherence and persistence to teriparatide treatment in patients attending a specialised Bone Health Service

Steen Georgina , Maher Niamh , Fallon Nessa , Dillon Aoife , Mahon James , Lannon Rosaleen , McCarroll Kevin , Walsh J B , Casey Miriam

Introduction: Osteoporosis affects the bones causing weak or brittle bones and increasing the risk of fracture. Efficacy of anti-osteoporotic treatment is based on drug potency and adherence and persistence. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis. It is usually given as a daily subcutaneous injection for a two-year treatment course.Aim: To evaluate adherence and persistence to TPTD treatment in patient...